A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases

Abstract Despite major therapeutic advances for two decades, including the most recently approved anti-HER2 drugs, brain metastatic localizations remain the major cause of death for women with metastatic HER2 breast cancer. The main reason is the limited drug passage of the blood-brain barrier after...

Полное описание

Библиографические подробности

Главные авторы:	Eurydice Angeli, Justine Paris, Olivier Le Tilly, Céline Desvignes, Guillaume Gapihan, Didier Boquet, Frédéric Pamoukdjian, Diaddin Hamdan, Marthe Rigal, Florence Poirier, Didier Lutomski, Feriel Azibani, Alexandre Mebazaa, Amaury Herbet, Aloïse Mabondzo, Géraldine Falgarone, Anne Janin, Gilles Paintaud, Guilhem Bousquet
Формат:	Artigo
Язык:	Inglês
Опубликовано:	BMC 2024-04-01
Серии:	Experimental Hematology & Oncology
Предметы:	HER2 breast cancer Brain metastases Fab Trastuzumab Pharmacokinetic
Online-ссылка:	https://doi.org/10.1186/s40164-024-00513-7
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!